FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to drugs and concerns using (2R,4R)-2-({[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-amino}-methyl)-chroman-4-ol or its pharmaceutically acceptable salts or solvates used for production of a drug for treatment of catalepsy. Also, invention proposes a pharmaceutical composition for treatment of catalepsy that comprises (2R,4R)-2-({[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-amino}-methyl)-chroman-4-ol as an active component taken in the pharmaceutically effective amount in combination with one or some pharmaceutically acceptable excipients.
EFFECT: valuable medicinal properties of compound and pharmaceutical composition.
3 cl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL USING 2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2002 |
|
RU2297833C2 |
| NEW APPLICATIONS | 2019 |
|
RU2836384C2 |
| METHODS FOR TREATMENT OF BEHAVIOR CHANGES | 2018 |
|
RU2799049C2 |
| CHROMON OXIME NEW DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2015 |
|
RU2672569C2 |
| 3R,4S 3-[4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDIN-1- YL)CHROHAN-4,7-DIOL, OPTICAL ISOMERS THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON, AND METHOD OF MEDICAL TREATMENT | 1994 |
|
RU2126404C1 |
| METHODS OF TREATING BORDERLINE PERSONALITY DISORDER | 2020 |
|
RU2833298C2 |
| SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO [3_2_0] HEPT-3-EN-6-ONE | 2016 |
|
RU2734475C2 |
| SYNERGETIC TREATMENT OF PARKINSONISM | 1995 |
|
RU2176145C2 |
| NOVEL USING SUBSTITUTED AMINOMETHYLCHROMANS IN TREATMENT OF MOTION DISORDER OR UNDESIRABLE EFFECT CAUSED BY AGENTS THAT ARE ADMINISTRATED IN TREATMENT OF EXTRAPYRAMID MOTION DISORDER | 2002 |
|
RU2320336C2 |
| NOVEL SALT FORM OF DOPAMINE AGONIST | 2006 |
|
RU2393153C2 |
